The University of Southampton
University of Southampton Institutional Repository

The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma

Flavell, David J., Warnes, Sarah L., Bryson, Christine J., Field, Sarah A., Noss, Armorel L., Packham, Graham and Flavell, Sopsamorn U. (2006) The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma British Journal of Haematology, 134, (2), pp. 157-170. (doi:10.1111/j.1365-2141.2006.06155.x). (PMID:16771848).

Record type: Article


The chimaeric anti-CD20 antibody rituximab (Rituxan) sensitises lymphoma cells to small molecule cytotoxic drugs and to protein toxins. We have explored the augmentive effect of rituximab on the anti-CD19 immunotoxin BU12-SAPORIN in a model of human lymphoma. Intact rituximab and its F(ab)(2) derivative both augmented the immunospecific protein synthesis inhibitory effects of BU12-SAPORIN in a complement-independent manner. A combination of rituximab + BU12-SAPORIN completely abolished the proliferation of Ramos cells in vitro and also induced a significantly greater degree of apoptosis in these cells. Treatment with rituximab, BU12-SAPORIN or a combination of both induced poly(ADPribose) polymerase and caspase 3 cleavage, although this was always consistently greater in combination-treated cells. zVAD almost completely inhibited apoptosis in rituximab- or BU12-SAPORIN-treated cells but only partially in combination-treated cells. In severe combined immunodeficient (SCID)-Ramos mice the combination of rituximab + BU12-SAPORIN was significantly better therapeutically than either single agent. The immunological fidelity of the therapeutic effect because of combination treatment was demonstrated through the failure of rituximab to augment an irrelevant anti-CD7 immunotoxin. The therapeutic efficacy of rituximab and combination treatment was reduced in SCID-Ramos mice depleted of serum complement while natural killer cell depletion failed to show any convincing role for antibody-dependent cellular cytotoxicity. This study shows a clear therapeutic advantage from using rituximab to immunospecifically augment immunotoxin cytotoxicity warranting further investigation.

Full text not available from this repository.

More information

Published date: July 2006
Keywords: malignant lymphomas, immunotherapy, apoptosis, antibody therapy


Local EPrints ID: 62739
ISSN: 0007-1048
PURE UUID: ebdce7e7-e250-43eb-baa2-0583e12ed7a1

Catalogue record

Date deposited: 17 Nov 2008
Last modified: 17 Jul 2017 14:20

Export record



Author: David J. Flavell
Author: Sarah L. Warnes
Author: Christine J. Bryson
Author: Sarah A. Field
Author: Armorel L. Noss
Author: Graham Packham
Author: Sopsamorn U. Flavell

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.